In contrast, CSF concentration of total tau and β-amyloid1-42 (Aβ1-42), plasma levels of Aβ1-42, AD Assessment Scale-Cognitive (ADAS-Cog) summary scores, MMSE, and Neuropsychiatric Inventory were the secondary outcomes. The gene discussed is MAPT; the disease is Alzheimer disease.